News | December 09, 2024
Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Subscribe To Our Newsletter & Stay Updated
